Methohexital

Generic Name: Methohexital

Brand Names: Brevital

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₈N_₂O_₃

CAS Number: 151-83-7

Unique Ingredient Identifier: E5B8ND5IPE

Overview

An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia.

Indication

诱导麻醉。

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Comparison of Esketamine/Propofol and Methohexital Anesthesia for ECT	2022/12/19	NCT05655754	Phase 4	Recruiting	Medical University of Vienna
Comparison of Bolus Dosing of Methohexital and Propofol in Elective Direct Current Cardioversion	2019/12/05	NCT04187196	Phase 4	Completed	Wake Forest University Health Sciences
EEG Characteristics in ECT	2019/07/17	NCT04022226	Early Phase 1	Completed	University of New Mexico
Ketamine Anesthesia for Improvement of Depression in ECT	2016/04/27	NCT02752724	Not Applicable	Completed	VA Puget Sound Health Care System
Methohexital v Propofol as General Anesthetic in Patients on ACEIs or ARBs	2015/12/08	NCT02624050	Not Applicable	Completed	Milton S. Hershey Medical Center
Enhancing the Effectiveness of Electroconvulsive Therapy in Severe Depression	2013/07/24	NCT01907217	Phase 4	Completed	St Patrick's Hospital, Ireland
Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression	2013/06/20	NCT01881763	Phase 4	Completed	Northwell Health
Use of Ketamine vs Methohexital for Electroconvulsive Therapy (ECT) on Patient Recovery and Re-orientation Time	2012/03/30	NCT01567852	Not Applicable	Completed	University of New Mexico
Ketamine Anesthesia in Electroconvulsive Therapy	2011/06/06	NCT01367119	Not Applicable	Completed	Mayo Clinic
Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in Depression	2011/03/07	NCT01309581	Not Applicable	Terminated	James Murrough

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Methohexital Sodium	ONESOURCE SPECIALTY PHARMA LIMITED	83270-003	INTRAVENOUS	500 mg in 500 mg	5/22/2025
Brevital Sodium	Par Pharmaceutical, Inc.	42023-105	INTRAMUSCULAR, INTRAVENOUS, RECTAL	500 mg in 1 1	1/29/2021

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
BRIETAL SODIUM AMPOULE 660	eli lilly canada inc	00128678	Powder For Solution - Intravenous	500 MG / AMP	12/31/1960

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

No news found

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.